Identification and characterization of RET fusions in advanced colorectal cancer
Citations Over TimeTop 10% of 2015 papers
Abstract
There is an unmet clinical need for molecularly directed therapies available for metastatic colorectal cancer. Comprehensive genomic profiling has the potential to identify actionable genomic alterations in colorectal cancer. Through comprehensive genomic profiling we prospectively identified 6 RET fusion kinases, including two novel fusions of CCDC6-RET and NCOA4-RET, in metastatic colorectal cancer (CRC) patients. RET fusion kinases represent a novel class of oncogenic driver in CRC and occurred at a 0.2% frequency without concurrent driver mutations, including KRAS, NRAS, BRAF, PIK3CA or other fusion tyrosine kinases. Multiple RET kinase inhibitors were cytotoxic to RET fusion kinase positive cancer cells and not RET fusion kinase negative CRC cells. The presence of a RET fusion kinase may identify a subset of metastatic CRC patients with a high response rate to RET kinase inhibition. This is the first characterization of RET fusions in CRC patients and highlights the therapeutic significance of prospective comprehensive genomic profiling in advanced CRC.
Related Papers
- → Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).(2013)43 cited
- → Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma(2012)24 cited
- → RAS status in Korean patients with stage III and IV colorectal cancer(2015)7 cited
- → Comprehensive Kras and Nras Mutation Analysis: Predictive Biomarkers in a Phase 3 Panitumumab Monotherapy Study of Metastatic Colorectal Cancer (Mcrc)(2013)2 cited
- → RAS mutations distribution in a 108 patients series of colorectal cancer(2014)